ASH 2014 | Phase Ib shows pembrolizumab elicits complete or partial remission in Hodgkin lymphoma

Name: Phase Ib shows pembrolizumab elicits complete or partial remission in Hodgkin lymphoma
Uploaded: 2015-04-09T14:37:52Z
Duration: 5 min 56 s
Description: At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Craig Moskowitz (Memorial Sloan Kettering Cancer Center, New York, NY) discusses the preliminary results of a phase Ib study evaluating the PD-1 inhibitor, pembrolizumab, in patients with classical Hodgkin lymphoma after brentuximab vedotin failure.

Craig Moskowitz • 9 Apr 2015

ASH 2014

Hodgkin Lymphoma Antibodies Brentuximab vedotin Checkpoint inhibitors Pembrolizumab

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Craig Moskowitz (Memorial Sloan Kettering Cancer Center, New York, NY) discusses the preliminary results of a phase Ib study evaluating the PD-1 inhibitor, pembrolizumab, in patients with classical Hodgkin lymphoma after brentuximab vedotin failure.